Page 2 - Sofinnova Ventures News Today

Ascendis Pharma A/S Announces Equity Investment in VISEN Pharmaceuticals – Advances Vision 3×3 to extend global clinical and commercial reach – COPENHAGEN, Denmark, Jan. 08, 2021 (GLOBE NEWSWIRE) — Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create product candidates that address unmet medical needs, today announced an equity investment of $12.5 million in VISEN Pharmaceuticals (VISEN) as part of VISEN’s $150...

Press release content from PR Newswire. The AP news staff was not involved in its creation. VISEN Pharmaceuticals Receives IND Approval to Initiate Phase 2 Clinical Trial of TransCon ™ CNP in Achondroplasia (ACH) in China January 7, 2021 GMT SHANGHAI, Jan. 7, 2021 /PRNewswire/ -- VISEN Pharmaceuticals, a biotech company committed to the treatment of endocrine-related diseases, introducing the world’s leading treatment methods and drugs into the China market and hoping to provide more Chines...